enGene Therapeutics (ENGN) stock

Gene therapy , market cap $113M

Gene therapy for bladder cancer

Worth $113M

$1.67

-5.65%

As of Tuesday's close · Live for Pro members at the open

Why is ENGN down?

Down 5.6% today, more than its biotech peers' 1.4%; no story names it yet.

Rose 15% since Nov 2

Up 15% from Nov 2 to Nov 10.

enGene Therapeutics rose 15% from Nov 2 to Nov 10. 12 points of it came on Nov 3.

Sources: Price history, Nov 10, 2026

Tell me next time ENGN moves

Free account, no card. An optional alert when ENGN moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →The other side, the timeline, and its peers, for Pro members.

Why ENGN still lags the market over three years

Down 71% over the year to Nov 9 while the S&P 500 rose 12%; up 15% since Nov 2.

1 reason, from its filings, with the timeline, for Pro members.

Quality Score

-7

Poor

In its industry

#241of 281

Biotech

Checks firing

2of 14

Transition

From 52-week high

-86.4%

under its best in a year

ENGN's Quality Score fell 3 points on Tue, Nov 10, to -7. Buying slipped from its highest in 20 days (3 chart checks stopped).

Follow ENGN's trial news. Pro members can get an alert when enGene Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ENGN files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…Phase 1 Pivotal Status Enrollment Complete: 12-Month Data Update Expected 2H 2026 First Patients…”Trial data · SEC filing · Aug 11

Cash$266M, about 10 quarters (2.5 years) at the last year's spendingOn Jul 31 · the company says “into 2H 2028”

Key facts on ENGN

Key facts on ENGN
Holding it back	36.5% more shares than a year ago
Latest filing	10-Q, Sep 8 Filed its quarterly report (10-Q) for the quarter to Jul 31, 2026

1 more reason behind ENGN's -7, free with an account →4 more reasons behind ENGN's -7, for Pro members.

ENGN in the news

TodayNo story names it yet.

What's next

Mon Nov 16: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Cash$266M, about 10 quarters (2.5 years) at the last year's spendingOn Jul 31 · the company says “into 2H 2028”

ENGN catalysts

Coming up

After its last 4 reports it closed +0.3% on average, higher 3 of 4 times.

What's next for ENGN, and how long its cash lasts

Next step the company has named

2H 2026“…2026 Cohort / NMIBC Indication Pre-Clinical Phase 1 Pivotal Status Enrollment Complete: 12-Month Data Update Expected 2H 2026 First Patients Enrolled: Ongoing Enrollment Complete N=30…”Trial data · SEC filing · Aug 11

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïvePhase 1/2 · Recruiting · 350 people · main data estimated Apr 30, 2028 · NCT04752722

For Pro members: 3 more milestones and 44 filings.

Cash runway Jul 31 balance sheet

About 10 quarters

$266M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2H 2028” (8-K, Mar 9).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 19, 2026)
At-the-market share sales program (424B5, filed Mar 9, 2026)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

An officer, William Grossman, bought 5,102 shares on Sep 22.

From Form 4: open-market buys and sales only.

Get an alert when Ronald Cooper buys or sells

For Pro members: every trade, and Ronald Cooper’s 13 filings and quotes.

Get an alert when ENGN files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ENGN scores -7

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

-7 is below -5, off the left end of the scale.

+2Chart checks 2 of 14 firing right now, one point each
−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years

Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Growth, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on ENGN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How ENGN ranks in Biotech

ENGN is #241 of 281 by Quality Score.

How ENGN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	EIKNEikon Therapeutics		Open for its score
	ELDNEledon Pharmaceuticals		Open for its score
	ENTXEntera Bio		Open for its score
	EPRXEupraxia Pharmaceuticals		Open for its score
241	ENGNenGene Therapeutics	2/14	-7

When does ENGN report earnings, and what happens after?

Expected to report Tue Dec 22, before the open (in 42 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ENGN reported on Sep 8, 2026

The quarter

The figures are not read from the release yet.

“The increase in net loss is mainly attributed to the increase in operating expenses, partially offset by net interest income earned during the period.”

The filing on EDGAR

Where the sales came from

ENGN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Research and development expenses decreased by $2.5 million, primarily driven by timing of process validation manufacturing activities in preparation to initiate the submission of a planned Biologics License Application with the FDA in the fourth quarter of 2026, partially offset by increased workforce reduction-related costs.”

From its results filing (SEC filing · Sep 8)

1 more sentence, for Pro members.

The numbers

Market value: $113M; today
Free cash flow: -$104M; last 12 months

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ENGN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+5.1%-18.8%+9.3%+5.5%

Dec 22Mar 9Jun 15Sep 8

Reported	When	Gap	Reaction	5 days
Sep 8, 2026Before open	Before open	0.0%	+5.5%	+2.8%
Jun 15, 2026Before open	Before open	+8.0%	+9.3%	+4.3%
Mar 9, 2026Before open	Before open	-7.1%	-18.8%	-17.5%
Dec 22, 2025After close	After close	0.0%	+5.1%	+2.0%

ENGN closed higher after 3 of its last 4 reports.

ENGN has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ENGN, and all 14 on every stock.Get in free →

ENGN RSI today: 49.3, below its 50-day and 200-day averages

Not scored

RSI 49.3, MACD above signal, below both averages. Not scored.13 readings

The deep dive on ENGN

What it does and how it makes money2 findingsFor Pro members2 findings on what ENGN does and how it makes money, for Pro members
Where it stands5 findings4 offerings of shares or notes since Nov 2024, $200M where the filing states the size.SEC filing · Mar 9, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ENGN, for Pro members

8 more findings on ENGN, each with its source, for Pro members.

ENGN share count over time

36% more shares than a year earlier.

Weighted shares, quarter to Jul 31, 2026, both from one filing

Shares of ENGN outstanding, as filed
Shares outstanding	As of
67M	Sep 2, 2026
67M	Jun 9, 2026
67M	Mar 3, 2026
67M	Feb 17, 2026

Offerings, shelves, and splits of ENGN, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 89% of its market value	Mar 9, 2026
Registered shares for a later sale (S-3)	Feb 19, 2026
Priced a sale of shares	Nov 14, 2025
Set up an at-the-market program for up to $100M of shares, about 89% of its market value	Dec 20, 2024

3 more offerings on file, for Pro members.

ENGN insider trades

One insider bought $10K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyWilliam Grossman$10KInterim Chief Medical Officerat $1.97 on Sep 22, filed Sep 24

BuyWilliam GrossmanInterim Chief Medical Officer$10Kat $1.97 on Sep 22, filed Sep 24

ENGN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

William GrossmanInterim Chief Medical Officer · 1 trade

See insider trades by person

About enGene Therapeutics

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

82 employeesSaint-Laurentengene.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ENGN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ENGN's score around: 8 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 24William Grossman bought ENGN$10K at $1.97, filed Sep 24

Alerts are optional.

See ENGN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ENGN's Quality Score is -7 (Poor), #241 of 281 in Biotech. Insiders bought $10K in the last 6 months (Form 4).

What does ENGN's Quality Score say?

ENGN scores -7 today, which Breakaway calls Poor. It is #241 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 15% from Nov 2 to Nov 10. Cash lasts about 10 quarters at its spending (to Jul 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ENGN's Quality Score?

ENGN scores -7 today, which Breakaway calls Poor (below zero). That is #241 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ENGN's -7.

Are insiders buying ENGN?

One insider bought $10K across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is William Grossman, Interim Chief Medical Officer, who bought $10K on Sep 22.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.